دورية أكاديمية

Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial

التفاصيل البيبلوغرافية
العنوان: Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial
المؤلفون: Beresford, MarkAff1, IDs44276023000168_cor1, Casbard, Angela, Hudson, Zoe, Carucci, Margherita, Ingarfield, Kate, Gee, Julia, Smith, Joanna, Kitson, Terri, Alchami, Fouad, Madden, Tracie-Ann, Hayward, Larrie, Hwang, David, Spensley, Saiqa, Waters, Simon, Wheatley, Duncan, Jones, Robert H.Aff3, Aff8
المصدر: BJC Reports. 1(1)
قاعدة البيانات: Springer Nature Journals
الوصف
تدمد:27319377
DOI:10.1038/s44276-023-00016-8